L. Uller (Lund, Sweden), F. Salgado Castro (Santiago De Compostela, Spain)
Introduction
L. Uller (Lund, Sweden), F. Salgado Castro (Santiago De Compostela, Spain)
|  |
Calcaratarin D reduces airway inflammation and oxidative damage by modulating alveolar macrophages via Michael acceptor system
W. Liao (Singapore, Singapore), Y. Foo (Singapore, Singapore), T. Tran (Singapore, Singapore), W. Wong (Singapore, Singapore)
|    |
Effect of tezepelumab on seasonal exacerbations in patients with severe, uncontrolled asthma grouped by blood eosinophil count
J. Corren (Los Angeles, United States), A. Menzies-Gow (London, United Kingdom), C. Ambrose (Gaithersburg, United States), G. Colice (Gaithersburg, United States), S. Roseti (Gaithersburg, United States), Å. Hellqvist (Gothenburg, Sweden), K. Kmita (Warsaw, Poland), A. Lindsley (Thousand Oaks, United States), B. Cook (Gaithersburg, United States)
| |
Extracellular HSP60 induces airway wall remodeling via Toll-Like-Receptors in mice
L. Fang (Basel, Switzerland), J. Li (Guangdong, China), L. Zhou (Basel, Switzerland), N. Segueni (Orléans, France), B. Ryffel (Orléans, France), M. Tamm (Basel, Switzerland), M. Roth (Basel, Switzerland)
| |
Identification of steroid-response pathways related to FeNO levels in asthma bronchial epithelium
M. Menzel (Copenhagen, Denmark), M. Hvidtfeldt (Copenhagen, Denmark), D. Klein (Copenhagen, Denmark), J. Nieto-Fontarigo (Lund, Sweden), A. Sverrild (Copenhagen, Denmark), L. Uller (Lund, Sweden), C. Porsbjerg (Copenhagen, Denmark)
| |
Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
I. Scott (Cambridge, United Kingdom), E. England (Cambridge, United Kingdom), D. Rees (Cambridge, United Kingdom), T. Erngren (Gothenburg, Sweden), C. Chaillan Huntington (Cambridge, United Kingdom), K. Houslay (Cambridge, United Kingdom), D. Sims (Gaithersburg, United States), C. Hollins (Cambridge, United Kingdom), E. Hinchy (Cambridge, United Kingdom), C. Colley (Cambridge, United Kingdom), D. Corkill (Cambridge, United Kingdom), E. Cohen (Cambridge, United Kingdom)
| |
Effects of anti-IL 17 on inflammation in Asthma, COPD and Asthma-COPD models
F. Almeida (São Paulo (SP), Brazil), L. Camargo (São Paulo (SP), Brazil), N. Martins (São Paulo (SP), Brazil), J. Lourenço (São Paulo (SP), Brazil), S. Bezerra (São Paulo (SP), Brazil), B. Saraiva-Romanholo (São Paulo (SP), Brazil), E. Leick (São Paulo (SP), Brazil), F. Q.S. Lopes (São Paulo (SP), Brazil), C. Prado (Santos (SP), Brazil), R. Righetti (São Paulo (SP), Brazil), I. Tibério (São Paulo (SP), Brazil)
| |
The impact of anti-IL5 therapies on patients with severe eosinophilic asthma: a proteomic approach
P. Cameli (Siena, Italy), L. Vantaggiato (Siena , Italy), M. D'Alessandro (Siena , Italy), L. Bergantini (Siena, Italy), E. Shaba (Siena, Italy), A. Carleo (Hannover, Germany), F. Di Giuseppe (Chieti, Italy), S. Angelucci (Chieti, Italy), L. Bini (Siena, Italy), E. Bargagli (Siena, Italy), C. Landi (Siena, Italy)
| |
Montelukast reverses ß2-adrenoceptor tolerance in airway smooth muscle and shows a synergic effect in vivo
I. Cerqua (Napoli, Italy), E. Granato (Napoli, Italy), M. Muscarà (São Paulo, Brazil), G. Cirino (Napoli, Italy), B. Severino (Napoli, Italy), R. Pavese (Salerno, Italy), A. Petti (Salerno, Italy), G. Caliendo (Napoli, Italy), F. Roviezzo (Napoli, Italy)
| |
THE PDE4 INHIBITOR TANIMILAST SHOWS DISTINCT IMMUNOMODULATORY PROPERTIES ASSOCIATED WITH A TYPE 2 ENDOTYPE AND CD141 UPREGULATION
H. Nguyen (Brescia (BS), Italy), V. Salvi (Brescia (BS), Italy), L. Tiberio (Brescia (BS), Italy), M. Govoni (Parma (PR), Italy), G. Villetti (Parma (PR), Italy), M. Civelli (Parma (PR), Italy), I. Barbazza (Brescia (BS), Italy), C. Gaudenzi (Brescia (BS), Italy), M. Passari (Brescia (BS), Italy), T. Schioppa (Brescia (BS), Italy), F. Sozio (Brescia (BS), Italy), A. Dal Prete (Brescia (BS), Italy), S. Sozzani (Rome (RM), Italy), D. Bosisio (Brescia (BS), Italy), F. Facchinetti (Parma (PR), Italy)
| |